Pfizer’s US Contract Sets The Financial Bar For COVID-19 Vaccines

The US government’s order of 100 million doses for $1.95bn means the implied price for Pfizer/BioNtech's vaccine is $19.50 per dose. That could set a benchmark for solid near-term revenue and profitability for companies in the space. 

profit text written on wooden block with stacked coins on grey background
Pfizer's appears poised to make a solid profit off of a COVID-19 vaccine • Source: Shutterstock

While the race to get a COVID-19 vaccine to market remains tight, Pfizer Inc. and BioNTech SE are leading the way when it comes to pricing. Their COVID-19 vaccine supply agreement with the US government for 100 million doses for $1.95bn sets a bar for implied pricing and profitability for vaccine players working in the space.

The companies and the US Department of Health and Human Services announced an agreement on 22 July under which the...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from COVID-19

More from Scrip